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A pilot randomized controlled trial of renal protection with
pioglitazone in diabetic nephropathy.
Background. Diabetic nephropathy progresses relentlessly
to end-stage renal disease (ESRD). Animal experiments
have found that peroxisome proliferator activated receptor-c
(PPAR-c)–based therapy can have a glucose independent ef-
fect on renal protection. We hypothesized that PPAR-c–based
antidiabetic therapy would result in greater reduction in pro-
teinuria compared to sulfonylurea-based therapy.
Methods. In 44 patients with overt diabetic nephropathy, an
open-label, blinded end point trial was conducted in which sub-
jects were randomized to either pioglitazone or glipizide to
achieve similar glucose control. Proteinuria was assessed by two
collections of 24-hour urine samples each month for 4 months.
Results. The glipizide group had an adjusted mean increase in
proteinuria of 6.1% (95% CI −11.7%, 23.8%), whereas the pi-
oglitazone group had a reduction of 7.2% (95% CI −24.9%,
10.6%). The adjusted reduction with pioglitazone of 13.2%
(95% CI −38.4%, 11.9%) was not statistically significant (P =
0.294). Baseline proteinuria, diastolic ambulatory blood pres-
sure, and serum albumin concentration were independent pre-
dictors of reduction in proteinuria. The frequency and patterns
of adverse events were similar in the two groups.
Conclusion. In patients with advanced diabetic nephropathy,
we found no reduction in proteinuria over 4 months. These data
are useful to design larger studies with longer duration of follow-
up to demonstrate renal protection of PPAR-c agonists.
Blood pressure control [1–3] using renin-angiotensin-
aldosterone system (RAAS) blockade [4–8] is the back-
bone of current strategies to slow the progression of re-
nal disease. It also is well recognized that proteinuria is a
marker of renal disease and that the intensity of protein-
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uria is predictive of the rate of decline in kidney func-
tion [9]. Patients who continue to have proteinuria de-
spite RAAS blockade progress to end-stage renal disease
(ESRD) and have more cardiovascular events compared
with those who do not have proteinuria [10]. Further-
more, the extent of reduction in protein excretion rate
after initiating an angiotensin-converting enzyme (ACE)
inhibitor [11] or angiotensin receptor blockade [9] is pre-
dictive of renal protection. Thus, the extent of protein-
uria and the degree of reduction with therapy serve as
excellent, independent risk markers for the progression
of renal disease [12].
Discovery of peroxisome proliferators-activated re-
ceptors (PPAR) has led to development of selective
receptor agonists for the treatment of insulin resistance
associated with type 2 diabetes mellitus [13]. Some unique
attributes of these drugs—independent of lowering glu-
cose [14]—offer hope of protecting the kidney from
progressive nephropathy [15–19]. These characteristics
include a lower systolic blood pressure [20], decrease
in triglyceride and increase in high-density lipoprotein
(HDL) cholesterol concentrations [20, 21], increased
linoleic acid/oleic acid ratio in the renal cortex, an ef-
fect that is relevant to the membrane fluidity and func-
tion [15], and improvement in endothelial and vascular
function [22] (for a recent review see [23]). PPAR-c re-
ceptors are present in glomeruli [16], mesangial cells and
podocytes, where they may have direct cytoprotective
effects [24–26] and may favorably influence glomerular
hemodynamics [22]. Certain genetic polymorphisms of
the PPAR-c receptors have been found to be protec-
tive of diabetic nephropathy [27]. In addition, activation
of PPAR-c receptors has anti-inflammatory [13, 28] and
antifibrotic [26] properties. Inflammation is a key event
for subsequent fibrosis in the pathogenesis of diabetic
nephropathy [29, 30] which suggests that PPAR-c ago-
nists with anti-inflammatory and vasodilatory effects may
favorably influence the outcome of diabetic nephropathy.
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Animal studies demonstrate that PPAR-c activation
is useful for the prevention and treatment of nephropa-
thy in Zucker fatty rats [15, 31]. Some studies in patients
with microalbuminuria have noted reductions in urinary
albumin excretion rate with PPAR-c agonists [28, 32–35].
However, the role this class of drugs has in more advanced
stages of diabetic nephropathy is less clear. In this pilot
investigation, we hypothesized that treatment with pi-
oglitazone would be renoprotective in patients with overt
type 2 diabetic nephropathy.
METHODS
Trial design
We conducted a randomized, open-label, blinded end
point study comparing glipizide with pioglitazone over 16
weeks. The end point was blinded to the personnel per-
forming the technical and data analysis until the end of
the trial. Blocked randomization stratified by proteinuria
(≤3 g and >3 g protein/creatinine ratio) was performed
and concealed by way of sequentially labeled opaque
sealed envelopes until intervention was assigned.
Protocol
Subjects. The study was approved by the Institutional
Review Board of Indiana University and the Research
and Development Committee of the Roudebush Veter-
ans Administration Medical Center in Indianapolis and
all patients gave their written informed consent. Patients
with established diabetic nephropathy were recruited
from the renal clinic at the Roudebush Veterans Adminis-
tration Medical Center in Indianapolis, Indiana. In order
to qualify for inclusion in the study, patients with type 2 di-
abetes requiring treatment with oral hypoglycemic drugs
or insulin were required to have a urine protein/creatinine
ratio of >1.0 g/g on a single voided specimen and a cre-
atinine clearance of >20 mL/min by Cockcroft-Gault
formula. Exclusion criteria included the presence of liver
disease, New York Heart Association (NYHA) class III
or IV heart failure, unstable angina, myocardial infarc-
tion, or stroke in the previous 3 months, nonsteroidal anti-
inflammatory drug (NSAID) use, or body mass index of
≥40 kg/m2.
Procedures
After a medical history and physical examination, 24-
hour urine samples were collected on two consecutive
days for analysis of sodium, potassium, urea, creatinine,
and protein at the hospital laboratory using standard
techniques. This procedure was repeated each month for
the 4-month duration of the study. Renal hemodynamics
were assessed at the beginning and at the end of study.
Glomerular filtration rate (GFR) was measured with an
ambulatory infusion of cold iothalamate [36] detected by
using high-performance liquid chromatography (HPLC)
[37]. Simultaneously, effective renal plasma flow (ERPF)
was measured using a 3-hour infusion of para-amino hip-
puric acid (PAH) and calculating the urinary clearance
in four half-hour intervals after the first hour of infusion
[38]. Ambulatory blood pressure monitoring using Space-
labs 90207 monitors at the initiation and completion of
the study was performed using standard techniques [39].
To assess adequacy of diabetes control hemoglobin A1c
(HbA1c) was measured at baseline and at the end of the
study.
Control of diabetes was managed by physicians not in-
volved with technical and data analysis in an open-label
fashion with a goal to reduce fasting blood glucose to
<140 mg/dL and HbA1c to <8%. Patients not receiving
any antidiabetic drug therapy were randomized to receive
either 5 mg glipizide or 15 mg pioglitazone. Drug titration
occurred at monthly intervals to achieve the desired glu-
cose control. If glucose control was at goal, insulin dose
was reduced to allow additional oral antidiabetic drug
use. Increments were made by 5 mg for glipizide and
15 mg for pioglitazone. Finally, the dose of insulin was
titrated if glucose control was not achieved. All patients
had monthly evaluation of liver function tests. Blood
pressure was controlled without increasing the dose or
adding an ACE inhibitor or angiotensin receptor blocker.
Blood pressure of 180/110 mm Hg or more mandated
treatment but lower levels were sometimes treated at the
discretion of the physician if thought to be unsafe for the
participant over the 4 months of the trial.
Sample size estimation
Based on data from previous studies in similar popula-
tions [40], our study had 80% power to detect a difference
of 40% reduction (10% reduction per month) in pro-
teinuria between treatments at a two sided significance
level of 0.05. This expected reduction was optimistic but
was calculated a priori. No prior studies had explored the
magnitude of reduction in proteinuria that is achievable
with pioglitazone in advanced diabetic nephropathy and
given this uncertainty, the pilot nature of this trial that
was to be performed at a single site, we reasoned that re-
cruiting 44 patients would be reasonable to estimate the
magnitude of reduction in proteinuria prior to perform-
ing larger trials.
Statistical analysis
Primary analyses involved detecting a difference in
daily urinary protein excretion between the two study
medications. Descriptive statistics were calculated for the
two groups and analyzed by unpaired t test or v 2 test as
appropriate.
Twenty-four–hour urine protein excretion was calcu-
lated per gram urinary creatinine. Results of the two
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102 subjects were eligible
54 subjects were enrolled
44 subjects were
randomized
22 subjects
randomized to
pioglitazone
22 subjects
randomized to
glipizide
1 subject
withdrew
consent
1 subject withdrew
consent
1 subject did not
present for final visit
1 subject died
40 subjects completed study
4 subjects failed screening following consent
6 subjects withdrew consent prior to randomization
Fig. 1. Trial profile showing the number of
subjects who were screened, randomized, and
completed the study.
24-hour urine collections for each visit were averaged to
reflect protein excretion rate at each monthly visit. For the
purposes of statistical analysis, the protein excretion rate
per gram creatinine was loge transformed. The change
in protein excretion rate at each monthly visit compared
to baseline visit was modeled using repeated measures
analysis of variance (ANOVA). The following were used
as explanatory variables: baseline proteinuria, ambula-
tory systolic and diastolic blood pressure, serum albu-
min, hemoglobin concentration, total cholesterol, HDL
cholesterol, triglyceride, HbA1c, and GFR. The nomi-
nal doses of each drug were modeled as time-dependent
covariate. The drug-versus-time interaction, after ac-
counting for the explanatory variables, was tested for a
two-sided significance value set at <0.05. All statistical
analyses were conducted using SAS version 9.1.
RESULTS
Study participants
A flow chart of subject participation is illustrated in
Figure 1. Subjects seeking care at the Roudebush Vet-
erans Administration Medical Center outpatient renal
clinic were screened for participation between Novem-
ber 2001 and July 2003. Of this population, 102 sub-
jects were eligible for participation. Fifty-four subjects
qualified and consented to participate in the study and
44 were randomized to treatment. Actual subject study
participation occurred between November 2001 and
December 2003. Two subjects withdrew following ran-
domization, one under advice of a primary care physician,
and the other following hospitalization for a gastrointesti-
nal bleed. One subject crossed over to glipizide after be-
ing randomized to pioglitazone. Two subjects randomized
to pioglitazone were discontinued from the study drug at
the second study visit. However, both continued and suc-
cessfully completed the study. One subject died due to
metastatic adenocarcinoma. Finally, one subject was un-
able to present for the final study visit. Thus, 40 subjects
(19 in the glipizide arm and 21 in the pioglitazone arm)
completed the study.
Subjects in each group were similar with respect
to baseline demographic and clinical characteristics
(Table 1). Baseline median 24-hour urine protein/g
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Table 1. Baseline Characteristics of the study population
Pioglitazone Glipizide
Age years 67 ± 8.5 64.1 ± 8.4
Males number (%) 22 (100) 22 (100)
White number (%) 19 (86) 16 (73)
Black number (%) 3 (14) 6 (27)
Height cm 173.8 ± 8.2 173.8 ± 7.6
Weight kg 97.5 ± 19.1 102.4 ± 18.9
Body mass index kg/m−2 32.2 ± 6.0 33.7 ± 5.0
Former smoker number (%) 18 (82) 17 (77)
Current Smoker number (%) 6 (27) 8 (36)
Current alcohol use number (%) 6 (27) 5 (23)
24-hour Systolic blood pressure 148.0 ± 17.4 152.8 ± 18.2
mm Hg
24-hour Diastolic blood pressure 74.8 ± 9.2 76.3 ± 10.6
mm Hg
24-hour Heart rate beats/min−1 70.8 ± 12.2 68.2 ± 11.4
Fasting glucose mg/dL 147 ± 58 155 ± 79
Hemoglobin A1c % 7.7 ± 2..2 7.7 ± 2.5
Blood urea nitrogen mg/dL 51.3 ± 26.8 36.1 ± 18.5
Albumin g/dL 3.7 ± 0.3 3.7 ± 0.4
Creatinine mg/dL 2.6 ± 1.1 2.4 ± 1.3
Total cholesterol mg/dL 194.8 ± 77.6 184.2 ± 49.9
LDL cholesterol mg/dL 101.8 ± 40.9 99.9 ± 40.7
HDL Cholesterol mg/dL 43.4 ± 10.8 41.2 ± 11.3
24-hour Urine sodium mEq/day∗∗∗ 180 ± 77 208 ± 75
Number of antihypertensive drugs 4.3 ± 1.8 4.1 ± 1.4
number
ACE inhibitor n (%) 10 (45) 13 (59)
Angiotensin II blocker number 10 (45) 9 (41)
Insulin number (%) 15 (68) 13 (59)
Oral hypoglycemic agents 10 (45%) 13 (59%)
number (%)
Duration of diabetes years 15.9 ± 8.0 14.3 ± 9.8
Vascular disease number (%) 14 (64) 14 (64)
None of the parameters were statistically different between the two groups.
Abbreviations are: LDL, low-density lipoprotein; HDL, high-density
lipoprotein; ACE, angiotensin-converting enzyme.
creatinine was 2.6 g [interquartile range (IQR) 1.8 to 4.2
g] in the pioglitazone treatment group and 2.8 g (IQR 1.5
to 5.0 g) in the glipizide group.
Level of proteinuria, ambulatory blood pressure, GFR,
and serum albumin can influence the change in 24-hour
protein excretion rate in response to antiproteinuric ther-
apy so these variables were used as covariates in assess-
ing the response to the drug. In univariate analysis, the
predictors of reduction in 24-hour protein excretion rate
were proteinuria, systolic and diastolic blood pressure,
albumin, and GFR. In a multivariate model, the inde-
pendent predictors were proteinuria, serum albumin, and
diastolic blood pressure (Table 2). Systolic blood pressure
and GFR were no longer significant in the multivariate
model. Furthermore, the reduction in proteinuria was not
predicted by baseline glycemic control, total cholesterol,
HDL cholesterol, triglycerides, or hemoglobin concen-
tration.
No overall reduction in proteinuria was noted during
the 4 months of study either in the pioglitazone group
(P = 0.42) or in the glipizide group (P = 0.49). The per-
cent changes in 24-hour protein excretion, adjusted for
Table 2. Baseline predictors of reduction in proteinuria in the
multivariable model
Estimate SE Estimate P value
Loge 24-hour protein/creatinine −0.30 0.064 <0.0001
ratio g/g
Serum albumin concentration −0.52 0.140 0.0006
g/dL
24-hour diastolic blood pressure −0.014 0.005 0.007
mm Hg
Negative numbers indicate an inverse relationship. Thus, a greater reduction in
proteinuria would be predicted for individuals with higher baseline proteinuria,
higher ambulatory 24-hour diastolic blood pressure, and a higher baseline serum
albumin concentration in this model.
baseline proteinuria, diastolic blood pressure and serum
albumin are shown in Figure 2. At none of the visits were
changes in proteinuria in the pioglitazone group signifi-
cantly different from the corresponding glipizide group.
There was no significant interaction effect between group
and visit. The glipizide group had an adjusted least mean
square increase of 6.1% (95% CI −11.7% to 23.8%),
whereas the pioglitazone group had an adjusted mean
reduction of 7.2% (95% CI −24.9% to 10.6%). The ad-
justed mean reduction with pioglitazone of 13.2% when
compared with glipizide (95% CI −38.4% to 11.9%)
was not statistically significant (P = 0.294). The mean
dose of pioglitazone was 33 ± 10 mg, mean maximal
dose 41 ± 10 mg and average exposure 3.8 ± 0.7 months.
The mean dose of glipizide was 16 ± 8 mg, mean maxi-
mal dose was 19 ± 11 mg, and the average exposure was
3.7 ± 0.8 months. No relationship between the dose of ei-
ther hypoglycemic agent and reduction in proteinuria was
seen. Finally, interaction between the covariates, serum
albumin, diastolic blood pressure, baseline proteinuria,
and randomized drug did not yield any significant effect.
Table 3 shows changes in ambulatory blood pressure,
renal hemodynamics, and the fasting lipid profiles. No
differences in any of these variables were observed with
either drug. Comparison of the differences between the
two drugs also was not significant for any of the parame-
ters tested.
Safety and adverse events
The number of serious adverse events was similar in
each randomized group. Seven subjects randomized to
pioglitazone experienced nine serious adverse events,
whereas seven subjects randomized to glipizide experi-
enced ten serious adverse events. The nature of these ad-
verse events is summarized in Table 4. Acute renal failure
was due to volume depletion in each subject reported.
Three subjects randomized to pioglitazone experi-
enced five adverse events: gout (N = 1), worsening
hypertension (N = 1), hyperkalemia (N = 1), and
hypoglycemia (N = 2). Eight subjects randomized to
glipizide experienced ten adverse events: hyperkalemia
Agarwal et al: Renal protection with pioglitazone 289
−40
−20
0
20
Pe
rc
e
n
t c
ha
ng
e 
in
 2
4-
ho
ur
u
rin
e 
pr
ot
ei
n 
ex
cr
e
tio
n 
ra
te
0 1 2 3 4
MonthsProteinuria g/d median (IQR)
Pioglitazone 3000 (1408) 2814 (2465) 2708 (2007) 2521 (2186) 2217 (2266)
Glipizide
Pioglitazone
Glipizide
3278 (2701) 3843 (1330) 3148 (2550) 3114 (3001) 3415 (3382)
Fig. 2. Percent change in 24-hour protein ex-
cretion/gram creatinine over the 4 months of
the study. Error bars are 95% CIs of the mean.
Overlap between CIs is seen at each time
point, reflecting no statistical difference be-
tween the two therapies. The median 24-hour
urine protein is shown at each visit for each
drug below the ordinate.
(N = 1), worsening hypertension (N = 1), worsening
edema (N = 2), hypoglycemia (N = 3), and infection
(N = 3). Two subjects discontinued the study drug, piogli-
tazone, one because of worsening angina and the other
because of malaise, fatigue, decreased appetite, insomnia,
constipation, and elevated blood glucose. In the latter pa-
tient, stopping the drug resulted in prompt resolution of
symptoms.
DISCUSSION
Our study, powered to detect 10% reduction in pro-
teinuria per month in favor of pioglitazone, did not find a
reduction in proteinuria of this magnitude. Reduction in
proteinuria of 13.2% favored pioglitazone. This informa-
tion will allow design of larger trials to test the efficacy
of pioglitazone in diabetic nephropathy. The short-term
reduction of proteinuria is the strongest determinant of
renal and cardiovascular protection in long-term clinical
trials in patients with type 2 diabetic nephropathy [9, 10].
Thus, the measurement of proteinuria as a surrogate end
point in this population appears appropriate for the de-
tection of renoprotective effects of PPAR-c agonists.
In patients with microalbuminuria, PPAR-c have been
found to be superior in reducing urinary albumin excre-
tion rates compared to other oral hypoglycemic agents
[28, 32–34]. For example, the withdrawn PPAR-c agonist,
troglitazone reduced microalbuminuria in type 2 diabetes
when compared to metformin over 12 weeks [32]. Trogli-
tazone reduced the median albumin:creatinine ratio from
70 to 40 mg/g creatinine at 4 weeks (P = 0.021) and main-
tained these reduced levels throughout the treatment pe-
riod. Metformin did not change the albumin:creatinine
ratio throughout the 12 weeks. Similarly, a 3-month trial
of pioglitazone reduced urinary endothelin-1 levels and
microalbuminuria in type 2 diabetes [35]. A 6-month trial
of treatment with pioglitazone in type 2 diabetic patients
with microalbuminuria resulted in reduced albumin ex-
cretion rate and podocyte excretion rate [28]. Urinary
albumin excretion decreased in subjects with microalbu-
minuria and type 2 diabetes who were randomized to 4 mg
twice daily of rosiglitazone for 26 weeks [33] or 52 weeks
[41]. However, Yanagawa et al [42] were unable to find su-
perior protection through pioglitazone compared to an-
other nonglitazone oral hypoglycemic agent, glicazide.
Finally, Nakamura et al [34] studied 32 normotensive
patients with type 2 diabetes mellitus with microalbumin-
uria (N = 16) or macroalbuminuria (N = 16) randomly as-
signed in equal numbers to troglitazone or glibenclamide.
Over a 1-year follow-up period, reduction in microalbu-
minuria and urinary excretion of type IV collagen was
seen in those with microalbuminuria assigned to troglita-
zone. No such changes were seen with glibenclamide in
either group or with troglitazone in the macroalbumin-
uric group.
Pioglitazone causes a dose-dependent increase in prox-
imal tubular albumin uptake but no concurrent increase
in inflammatory and profibrotic markers in cultured prox-
imal tubular cells [28]. Low-density lipoprotein (LDL)
and albumin also increase inflammatory and profibrotic
markers in these cells. Although pioglitazone reverses
the inflammatory and profibrotic response to LDL, it
fails to elicit this response to albumin exposure. Thus,
pioglitazone may be more effective in abrogating the
component of renal dysfunction attributable to dyslipi-
demia than that attributable primarily to albuminuria.
The anti-inflammatory response of pioglitazone was inde-
pendent of nuclear factor-jB (NF-jB) activity. Since the
latter is a major mechanism of renal protection for RAAS
blockers, the PPAR-c and RAAS blockers may have syn-
ergistic effects. Whether, renal protection would occur
independent of RAAS use cannot be answered by our
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Table 4. Serious adverse events
Pioglitazone Glipizide
Total events 9 10
Number of subjects experiencing events 7 7
Hospitalized heart failure 2 2
Asthma exacerbation 0 1
Accelerated hypertension 1 1
Hypoglycemia 2 1
Angina 1 0
Cancer 1 0
Infection 1 1
Acute renal failure 1 1
Hyperkalemia 0 1
Gastrointestinal bleeding 0 1
Cardiac arrhythmia 0 1
Death 0 1
study due to high percentage of our patients being on
RAAS inhibitors.
Baseline proteinuria, diastolic blood pressure, and
serum albumin concentration were independent predic-
tors of reduction in urine protein excretion rate over
4 months. Systolic blood pressure, GFR, fasting lipid
profile, glycemic control judged by HbA1c, and blood
hemoglobin concentration were not independent predic-
tors of reduction in proteinuria. Consistent with the ob-
servations of others [34], we did not find reduction in
proteinuria in our patients who all had macroalbumin-
uria; it is therefore tempting to postulate that the diabetic
nephropathy is so advanced that renal repair is not feasi-
ble. Nevertheless, reduction in overall protein excretion
rate in our study of 13.2% is reason for conducting larger
studies to detect smaller changes in protein excretion rate.
The adverse effects seen with the two agents were sim-
ilar. Notably, we found a similar incidence of hyperten-
sion and heart failure in the two groups. PPAR-c has been
associated with volume overload and the occurrence of
heart failure [43]. However, the number of patients expe-
riencing heart failure and hypertension were identical in
the two groups. Despite a short follow-up, the incidence
of accelerated hypertension and heart failure in this pop-
ulation was high even in the glipizide group. Although
the increased risk of events to PPAR-c may be conferred
by the underlying cardiorenal disease, long-term studies
will be needed to demonstrate the cardiovascular safety
of this class of drugs [44].
The strengths of our study are the measurements of
GFR, ambulatory blood pressure monitoring, and 48-
hour urine protein collection at each clinic visit. These
measurements improved the precision of blood pressure,
renal hemodynamics, and proteinuria. Limitations of our
study are the relatively short follow-up and limited num-
ber of subjects. It is conceivable that a longer duration
of exposure to pioglitazone or recruiting a larger number
of subjects or both would make the clinically significant
reduction of proteinuria, statistically significant.
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CONCLUSION
In this pilot single-center trial in patients with advanced
type 2 diabetic nephropathy we found 13.2% reduction in
proteinuria with pioglitazone when compared to glipizide
over 4 months. This point estimate of the magnitude of
reduction in proteinuria will allow design of larger stud-
ies with longer duration of follow-up to demonstrate re-
nal protection of PPAR-c, if one truly exists, in patients
with advanced diabetic nephropathy. Specifically 205 pa-
tients will be needed randomized to each group to see a
15% reduction in proteinuria with 80% power at a two-
sided significance level set at 5%. Exposure to the max-
imum dose of pioglitazone for a longer time period may
be needed to see this effect. Since proteinuria reduction
was influenced by baseline proteinuria, serum albumin
concentration, and diastolic ambulatory blood pressure,
these characteristics should be matched or a stratifica-
tion strategy adopted in the design of prospective trials.
The independent effect of this class of drugs to impact
macrovascular disease offers further impetus in explor-
ing cardiorenal protection [45].
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